Leti Joins DARPA-funded Consortium of Seeing and Hearing Foundation to Develop Implantable Device for Restoring Vision
[ Back ]   [ More News ]   [ Home ]
Leti Joins DARPA-funded Consortium of Seeing and Hearing Foundation to Develop Implantable Device for Restoring Vision

GRENOBLE, France – Nov. 09, 2017 – Leti announced today that a team of its researchers is participating in a U.S.-funded project to develop a safe, implantable neural interface system to restore vision by stimulating the visual cortex.

Funded by the U.S. Defense Advanced Research Projects Agency (DARPA), the Neural Engineering System Design program (NESD) sets out to expand neurotechnology capabilities and provide a foundation for future treatments of sensory deficits.

Scientists from Leti and Clinatec, Leti’s biomedical research center focused on applying micro- and nanotechnology innovations to health care, are part of a consortium conducted by the Paris Vision Institute under the leadership of Prof. José-Alain Sahel and Dr. Serge Picaud. The Vision Institute is a leading European research center in eye diseases, and is part of the Seeing and Hearing Foundation (Fondation Voir et Entendre, FVE), which was awarded the DARPA grant.

The FVE team project, called CorticalSight, is part of the six projects selected by DARPA to participate in the groundbreaking NESD program. CorticalSight will apply techniques from the field of optogenetics to enable communication between neurons in the visual cortex and a camera-based, high-definition artificial retina worn over the eyes. Leti will lead the development of the active implantable medical device that will interface with the visual cortex.

Clinatec and its Leti partners will focus on developing a safe, wireless, implantable system that restores vision through light stimulation of optogenetically modified neurons in the visual cortex. Leti is tasked with designing an implantable device, as well as creating hermetic packaging and radiofrequency links for the implantable system, and subsequently conducting technical test benches. The Leti implant will enable visual cortex optical-stimulation patterns, and integrate the underlying control electronics within a minimally invasive cortical implant.

“Clinatec’s integrated approach to high-tech, medical-device R&D, extending from Leti’s technological development to in-house clinical expertise and testing capabilities, allows our teams to address cutting-edge medtech development challenges,” said Prof. Alim-Louis Benabid, Clinatec’s chairman of the board, and co-investigator of the CorticalSight project. “This contribution to the CorticalSight consortium will pave the way to new therapeutic devices for vision restoration thanks to the NESD program.”

Partners of the CorticalSight project also include the French companies Chronocam® and Gensight®, Stanford University, Inscopix® and the Friedrich Miescher Institute of Switzerland.

About Leti (France)

Leti, a technology research institute at CEA Tech, is a global leader in miniaturization technologies enabling smart, energy-efficient and secure solutions for industry. Founded in 1967, Leti pioneers micro-& nanotechnologies, tailoring differentiating applicative solutions for global companies, SMEs and startups. Leti tackles critical challenges in healthcare, energy and digital migration. From sensors to data processing and computing solutions, Leti’s multidisciplinary teams deliver solid expertise, leveraging world-class pre-industrialization facilities. With a staff of more than 1,900, a portfolio of 2,700 patents, 91,500 sq. ft. of cleanroom space and a clear IP policy, the institute is based in Grenoble, France, and has offices in Silicon Valley and Tokyo. Leti has launched 60 startups and is a member of the Carnot Institutes network. This year, the institute celebrates its 50th anniversary. Follow us on www.leti-cea.com and @CEA_Leti. Follow us on www.leti.fr/en and @CEA_Leti.

CEA Tech is the technology research branch of the French Alternative Energies and Atomic Energy Commission (CEA), a key player in innovative R&D, defence & security, nuclear energy, technological research for industry and fundamental science, identified by Thomson Reuters as the second most innovative research organization in the world. CEA Tech leverages a unique innovation-driven culture and unrivalled expertise to develop and disseminate new technologies for industry, helping to create high-end products and provide a competitive edge.

About Clinatec

Clinatec – The Edmond J. Safra Biomedical Research Center conducts research on the frontier of health care and micro- and nanoelectronics. Its teams of medical doctors, biologists, mathematicians, engineers and other specialists bring a unique, multi-disciplinary approach to diagnosis and treatment of neurodegenerative diseases, cancer and motor disabilities, and development of innovative biomedical devices to improve patient lives. The teams are comprised of personnel from the CEA, Grenoble-Alpes University Hospital, Université Grenoble-Alpes and INSERM. Clinatec is based in Grenoble, France, within the CEA research center. Visit www.clinatec.fr/en/.

Press Contact


+33 6 74 93 23 47

Email Contact    

Read the complete story ...